NEUROCRINE BIOSCIENCES, INC.
- Country
- 🇸🇪Sweden
- Ownership
- Public
- Established
- 1992-01-01
- Employees
- 1.4K
- Market Cap
- $15.4B
- Website
- http://www.neurocrine.com
Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
- First Posted Date
- 2018-02-23
- Last Posted Date
- 2022-02-23
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 85
- Registration Number
- NCT03444038
- Locations
- 🇵🇷
Neurocrine Clinical Site, San Juan, Puerto Rico
A Study to Evaluate 3 Dose Levels of Luvadaxistat of Adults With Negative Symptoms of Schizophrenia
- First Posted Date
- 2017-12-26
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 256
- Registration Number
- NCT03382639
- Locations
- 🇺🇸
Semel Institute for Neuroscience and Human Behavior, Los Angeles, California, United States
🇵🇱NZOZ Poradnia Zdrowia Psychicznego, Kobierzyce, Poland
🇵🇱Centrum Medyczne Plejady, Krakow, Poland
A Study to Evaluate Multiple Oral Doses of Luvadaxistat in Adults With Schizophrenia
- First Posted Date
- 2017-12-02
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 31
- Registration Number
- NCT03359785
- Locations
- 🇺🇸
CBH Health, LLC, Gaithersburg, Maryland, United States
Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome
- First Posted Date
- 2017-10-30
- Last Posted Date
- 2021-06-28
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 127
- Registration Number
- NCT03325010
- Locations
- 🇵🇷
Neurocrine Clinical Site, San Juan, Puerto Rico
A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia
- Conditions
- Stable Schizophrenia
- Interventions
- First Posted Date
- 2017-10-24
- Last Posted Date
- 2021-03-19
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 23
- Registration Number
- NCT03319953
- Locations
- 🇬🇧
Kings College London, London, United Kingdom
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Healthy Participants
- Conditions
- Healthy
- Interventions
- Drug: PlaceboDrug: TAK-831 Tablet T2Drug: TAK-831 Suspension
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 50
- Registration Number
- NCT03224325
- Locations
- 🇺🇸
California Clinical Trials Medical Group/PAREXEL, Glendale, California, United States
Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 67
- Registration Number
- NCT03214588
- Locations
- 🇺🇸
UCLA Ataxia Center, Los Angeles, California, United States
🇺🇸Ohio State University Wexner Medical Center, Columbus, Ohio, United States
🇺🇸USF College of Medicine, Tampa, Florida, United States
A Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 Tablet Formulation
- First Posted Date
- 2017-04-05
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 15
- Registration Number
- NCT03101293
- Locations
- 🇺🇸
PRA Health Sciences, Lenexa, Kansas, United States
Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease
- Conditions
- Idiopathic Parkinson's DiseaseParkinson's DiseaseBasal Ganglia DiseaseBrain DiseasesCentral Nervous System DiseasesMovement DisordersNervous System DiseasesNeurodegenerative DiseasesParkinsonian Disorders
- Interventions
- First Posted Date
- 2017-02-27
- Last Posted Date
- 2022-03-21
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 16
- Registration Number
- NCT03065192
- Locations
- 🇺🇸
University of California, San Francisco (UCSF), San Francisco, California, United States
🇺🇸Emory University, Atlanta, Georgia, United States
🇺🇸University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania, United States
Real-World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents
- Conditions
- Tardive Dyskinesia
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2017-11-22
- Lead Sponsor
- Neurocrine Biosciences
- Target Recruit Count
- 70
- Registration Number
- NCT03062033
- Locations
- 🇺🇸
Neurocrine Clinical Site, Bellevue, Washington, United States